Biomarkers

From Biomarkers to Companion Diagnostics: Advances in Immuno-Oncology Clinical Trial Assay Development – Broadcast 2

From Biomarkers to Companion Diagnostics: Advances in Immuno-Oncology Clinical Trial Assay Development – Broadcast 1

Ligand Binding Assays and Hybrid LC-MS Quantitation of Biotherapeutics and Biomarkers

Biomarkers in NASH Drug Development: Using Cytokeratin 18 as a Secondary Endpoint in Clinical Trials

Identifying Spatial Expression Patterns in the Tumor Microenvironment – Broadcast 2

Identifying Spatial Expression Patterns in the Tumor Microenvironment – Broadcast 1
Life Science News

Here’s Why Brain Biomarkers of Alzheimer’s Don’t Always Lead to Dementia
Biotech News

New Method Collects Circulating Tumor Cells from Blood Samples to be Used in Liquid Biopsy

Current Regulatory Guidelines for Human Biospecimens & Patient Consent in Clinical Research

Immunoprecipitation of Disease-Associated Proteins for Alzheimer’s Research

Leveraging Key Biomarkers to Advance Immuno-Oncology Drug Development and Find the Right Trial Participants

Adaptive Trial Design and Incorporation of Biomarkers to Maximize Achievable Objectives in Early Phase Clinical Studies

Quantitative Immunohistochemistry for Development of Predictive Biomarkers in Oncology Clinical Trials

Drug-Induced Organ Toxicity (DIOT): The Early Detection and Management of Elevated Biomarkers to Ensure Patient Safety

Quantitative Analysis of Biomarkers with the Specificity and Robustness of Liquid Chromatography/Mass Spectrometry (LC/MS) and the Sensitivity of ELISA